1. Home
  2. ABVC

as 05-24-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

Founded: 2015 Country:
United States
United States
Employees: N/A City: FREMONT
Market Cap: 10.1M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 1.1M
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.25 EPS Growth: N/A
52 Week Low/High: $0.67 - $7.04 Next Earning Date: 05-28-2024
Revenue: $25,363 Revenue Growth: -97.63%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Latest ABVC BioPharma Inc. News

ABVC Breaking Stock News: Dive into ABVC Ticker-Specific Updates for Smart Investing

All ABVC News

Share on Social Networks: